Anemia is a common but neglected complication of adjuvant chemotherapy for early breast cancer

Current Oncology

Volumn 14, Issue 6, 2007, Pages 227-233

  Goldrick, A ^a,b   Olivotto, Ivo A ^a,c   Alexander, C S ^a   Speers, C H ^a   Barnett, J ^a   Allan, S J ^a,c   Truong, P T ^a,c  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b LIVERPOOL HOSPITAL   (Australia)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Anemia; breast cancer; chemotherapy; epoetin; transfusion

Indexed keywords

EID: 48749097414     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.2007.155     Document Type: Article

References (27)

1. Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 1999; 91:1616–34.
2. Ray–Coquard I, Le Cesne A, Rubio MT, et al. Risk model for severe anemia requiring red blood cell transfusion after cytotoxic conventional chemotherapy regimens. The Elypse 1 Study Group. J Clin Oncol 1999;17:2840–6.
3. Dranitsaris G, Clemons M, Verma S, Lau C, Vincent M. Chemotherapy-induced anaemia during adjuvant treatment for breast cancer: development of a prediction model. Lancet Oncol 2005;6:856–63.
4. Seshadri T, Prince HM, Bell DR, et al. for the Australian Cancer Anaemia Study Group. The Australian Cancer Anaemia Survey: a snapshot of anaemia in adult patients with cancer. Med J Aust 2005;182:453–7.
5. Barrett–Lee P, Bokemeyer C, Gascon P, et al. Management of cancer-related anemia in patients with breast or gynecologic cancer: new insights based on results from the European Cancer Anemia Survey. Oncologist 2005;10:743–57.
6. Cella D, Kallich J, McDermott A, Xu X. The longitudinal relationship of hemoglobin, fatigue, and quality of life in anemic cancer patients: results from five randomized clinical trials. Ann Oncol 2004;15:979–86.
7. Lind M, Vernon C, Cruickshank D, et al. The level of hemo globin in anemic cancer patients correlates positively with quality of life. Br J Cancer 2002;86:1243–9.
8. Rizzo JD, Lichtin AE, Woolf SH, et al. Use of epoetin in patients with cancer: evidenced-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. Blood 2002;100:2303–20.
9. Crawford J, Cella D, Cleeland CS, et al. Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer 2002;95:888–95.
10. Cella D, Dobrez D, Glaspy J. Control of cancer-related anemia with erythropoietic agents: a review of evidence for improved quality of life and clinical outcomes. Ann Oncol 2003; 14:511–19.
11. Chang J, Couture F, Young S, McWatters KL, Lau CY. Weekly epoetin alfa maintains hemoglobin, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapy. J Clin Oncol 2005;23:2597–605.
12. Witzig TE, Silberstein PT, Loprinzi CL, et al. Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy. J Clin Oncol 2005;23:2606–17.
13. Demetri GD, Kris M, Wade J, Degos L, Cella D for the Procrit Study Group. Quality-of-life benefit in chemotherapy patients treated epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. J Clin Oncol 1998;16:3412–25.
14. Littlewood TJ, Bejetta E, Nortier W. Effects of epoetin alfa on hematologic parameters and QOL in cancer patients receiving nonplatinum chemotherapy: results of a randomized, doubleblind, placebo-controlled trial. J Clin Oncol 2001;19:2865–74.
15. Carelle N, Piotto E, Bellanger A, Germanaud J, Thuillier A, Khayat D. Changing patient perceptions of the side effects of cancer chemotherapy. Cancer 2002;95:155–63.
16. Fisher B, Brown AM, Dimitrov NV, et al. Two months of doxorubicin–cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol 1990;8:1483–96.
17. Levine MN, Pritchard KI, Bramwell VH, Shepherd LE, Tu D, Paul N, for the National Cancer Institute of Canada Clinical Trials Group. Randomized trial comparing cyclophosphamide, epirubicin and fluorouracil with cyclophosphamide, methotrexate and fluorouracil in premenopausal women with nodepositive breast cancer: update of National Cancer Institute of Canada Clinical Trials Group Trial MA5. J Clin Oncol 2005; 23:5166–70.
18. Henderson IC, Berry DA, Demetri GD, et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003;21:976–83.
19. Bonneterre J, Roche H, Kerbrat P, et al. Epirubicin increases long-term survival in adjuvant chemotherapy of patients with poor-prognosis, node-positive, early-stage breast cancer: 10-year follow-up results of the French Adjuvant Study Group 05 randomized trial. J Clin Oncol 2005;23:2686–93.
20. Caggiano V, Gupta S, Tannous RE. Chemotherapy-induced anemia in early-stage breast cancer. J Oncol Pharm Pract 2001; 7:1–6.
21. Kirshner J, Hatch M, Hennessy DD, Fridman M, Tannous RE. Anemia in stage II and III breast cancer patients treated with adjuvant doxorubicin and cyclophosphamide chemotherapy. Oncologist 2004;9:25–32.
22. Denison U, Baumann J, Peters–Engl C, et al. Incidence of anemia in breast cancer patients receiving adjuvant chemotherapy. Breast Cancer Res Treat 2003;79:347–53.
23. Jefford M, Savulescu J, Thomson J, et al. Medical paternalism and expensive unsubsidized drugs. BMJ 2005;331:1075–7.
24. Thomson J, Schofield P, Mileshkin L, et al. Do oncologists discuss expensive anti-cancer drugs with their patients? Ann Oncol 2006;17:702–8.
25. Arcasoy MO, Amin K, Karayal AF, et al. Functional significance of erythropoietin receptor expression in breast cancer. Lab Invest 2002;82:911–18.
26. Lester RD, Jo M, Campana WM, Gonias SL. Erythropoietin promotes MCF-7 breast cancer cell migration by an ERK/mitogen–activated protein kinase–dependent pathway and is primarily responsible for the increase in migration observed in hypoxia. J Biol Chem 2005;280:3927–37.
27. Acs G, Chen M, Xu X, Acs P, Verma A, Koch CJ. Autocrine erythropoietin signaling inhibits hypoxia-induced apoptosis in human breast carcinoma cells. Cancer Lett 2004;214: 243–51.